Ohta, Ibaraki
Akihiko Ohta, Ibaraki JP
Patent application number | Description | Published |
---|---|---|
20100089877 | WELDING METHOD USING WELDING MATERIAL HAVING LOW TRANSFORMATION TEMPERATURE - An arc welding method using a welding material having a low transformation temperature, characterized in that it is carried out by the use of a shielding gas consisting of a rare gas alone or a mixed gas of a rare gas and a small amount of an oxygen gas; and an additional welding method using a welding material having a low transformation temperature, characterized in that it is carried out while moving a weld line in the form of a straight line. The former method allows the enhancement of a Charpy value in combination with improved fatigue strength, and the latter allows the experience of heat history of the material having a low transformation temperature to be suppressed, resulting in the prevention of weld crack in combination with an improved fatigue strength. | 04-15-2010 |
Hisashi Ohta, Ibaraki JP
Patent application number | Description | Published |
---|---|---|
20090025095 | Method for Evaluating Compound Using Barlp and Substance for Regulating Eating and Body Weight - It is intended to provide a method for evaluating a compound which regulates eating or body weight characterized by comprising the steps of introducing a BARLP gene and preparing a cell expressing BARLP; bringing a test compound into contact with the cell; and detecting a specific binding of the test compound to the BARLP and a method for evaluating a compound further comprising the step of evaluating a test compound using a nonhuman genetically-engineered animal in which the BARLP gene is inactivated. According to this invention, knowledge about a relationship between BARLP and biological functions is obtained and a method for evaluating a compound targeting BARLP and a BARLP ligand obtained by the evaluation can be provided. | 01-22-2009 |
20090062293 | 1,4-Substituted Piperazine Derivatives - A compound represented by the formula (I): | 03-05-2009 |
20090275617 | Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds - Disclosed is an aryl-substituted nitrogen-containing heterocyclic compound represented by the formula (I) below or a pharmaceutically acceptable salt thereof. This compound serves as nociceptin receptor antagonist and is useful as a pharmaceutical agent for treating diseases associated with a nociceptin receptor. (I) | 11-05-2009 |
Narumi Ohta, Ibaraki JP
Patent application number | Description | Published |
---|---|---|
20090081554 | ALL-SOLID LITHIUM BATTERY - An all-solid lithium secondary battery has excellent reliability including safety. However, in general, its energy density or output density is lower than that achieved by liquid electrolyte systems. | 03-26-2009 |
Noriya Ohta, Ibaraki JP
Patent application number | Description | Published |
---|---|---|
20090170126 | Prostasin Partial Peptide and Anti-Prostasin Antibody - An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen. | 07-02-2009 |
Shuji Ohta, Ibaraki JP
Patent application number | Description | Published |
---|---|---|
20100279296 | ENHANCED FC RECEPTOR-MEDIATED TUMOR NECROSIS FACTOR SUPERFAMILY MRNA EXPRESSION IN PERIPHERAL BLOOD LEUKOCYTES IN PATIENTS WITH RHEUMATOID ARTHRITIS - A method for predicting patient responsiveness to rheumatoid arthritis treatments involving altering expression of tumor necrosis factor superfamily (“TNFSF”)-2, TNFSF-8, or TNFSF-15 is disclosed. A method for monitoring the effectiveness of such therapy is also disclosed. Furthermore, a method of screening compounds for use in the treatment of rheumatoid arthritis is disclosed. A method of monitoring the disease state over time in rheumatoid arthritis patients is also disclosed. | 11-04-2010 |
Yoshikazu Ohta, Ibaraki JP
Patent application number | Description | Published |
---|---|---|
20100008912 | COMBINATION DRUG - The present invention provides a pharmaceutical agent containing an HER2 inhibitor and a hormonal therapeutic agent or anti-cancer agent in combination. The present invention provides a pharmaceutical agent containing (1) an HER2 inhibitor having a pyrrolopyrimidine skeleton or pyrazolopyrimidine skeleton, and (2) a hormonal therapeutic agent or an anti-cancer agent in combination. | 01-14-2010 |